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Correspondence
There is no PF for TCDD currently
available in the Integrated Risk Information
Service database (3). However, the PF origi-
nally derived from the aforementioned
study was 156,000 mg/kg/day and may be
modified downward to approximately
100,000 mg/kg/day, based on reinterpreta-
tion of histopathologic data. Applying van
Birgelen's TEF to these values would sug-
gest a PF for the carcinogenic action of
HCB (under the linearized multistage
assumptions) to be approximately 10-16
mg/kg/day, or about an order ofmagnitude
more potent than issuggested by the in vivo
data. It is possible that the difference lies in
pharmacokinetic or pharmacodynamic fac-
tors that exist in the whole animal, which
cannot becaptured incellular assays.
As van Birgelen points out (1), the
World Health Organization indicates a
preference for long-term in vivo studies
over in vitro measures when setting a TEF
(5). The HCB example illustrates the
extreme caution that should be exercised
when applying a TEF based solely on in
vitro information, particularly when major
public health claims are being made.
BradleyW. Schwab
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Response:
Hexachlorobenzene
I appreciate Schwab's comments regarding
caution in the use of a toxic equivalency
factor (TEF) for hexachlorobenzene
(HCB) based on results of in vitro studies.
The dioxinlike effects of HCB include
cytochrome P4501A induction and bind-
ing to the aryl hydrocarbon (Ah) receptor.
In addition, HCB has been shown to
bioaccumulate. These three factors are a
prerequisite to include a compound in the
TEF concept, which compares the potency
ofa dioxinlike compound to 2,3,7,8-tetra-
chlorodibenzo-p-dioxin (TCDD). TEFs
are consensus values based on available
data on relative potency values for specific
compounds (1). TEF values are used to
estimate the total dioxin activity in envi-
ronmental and human samples by multi-
plying the TEF value by the concentration
of each compound, leading to a certain
amount of toxic equivalents (TEQs) for
each compound. The summation of all
TEQs in a certain mixture expresses the
total dioxin activity ofthis mixture. Based
on the binding affinity of HCB to the Ah
receptor, in vitro cytochrome P4501A
induction, and porphyrin accumulation, a
relative potency of 0.0001 for HCB was
estimated (X). Using this relative potency
value suggested that HCB could lead to a
considerable contribution to the dioxin
activity ofhuman milk in some countries.
I did not estimate the slope factor for HCB
that is used in carcinogenicity assessment.
The slope factor is the result ofthe applica-
tion ofa low-dose extrapolation procedure
and is presented as the risk per milligram
per kilogram of body weight per day
(mglkg/day) (3).
Schwab's comments included the com-
parison of these slope factors (although
potency factors are mentioned) for HCB
(1.6 per mg/kg/day) and TCDD (100,000
or 156,000 per mglkg/day). The slope fac-
tors for TCDD are not available in the
Integrated RiskInformation Service database
(3), as Schwab mentioned. He points out
correctly that the ratio between these two
slope factors is different from the suggested
relative potencyvalue for HCB. He assumes
byusing this approach thatTEFs would pre-
dict the carcinogenic potential ofdioxinlike
compounds. However, no studies have been
performed to verify this approach. Studies
are currently under way to determine
whether relative potency values based on
biochemical effects are predictive for car-
cinogenesis in female Sprague Dawley rats
forvarious dioxinlike compounds (4).
Angilique PJ.M. van Birgelen
NIEHS
Research Triangle Park, North Carolina
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